Arcus discloses $119.7M in financings

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) emerged from stealth mode and disclosed it has raised $119.7 million raised in combined series A and B rounds. CEO Terry Rosen told BioCentury the company expects to move its two most advanced programs into the clinic next year, and said the funding should provide runway through YE18.

Arcus raised $30 million in a series A round last year from company founders and friends and family, then expanded the round to $49.7 million with the addition of Novartis AG (NYSE:NVS; SIX:NOVN), Celgene Corp. (NASDAQ:CELG), the Column Group and Foresite Capital. ...